| Hitech Prosthetic, Inc. | |
| 39 Ave Severiano Cuevas, Carr 107, Aguadilla, Puerto Rico 00603 | |
| (787) 891-4805 |
| Name | Hitech Prosthetic, Inc. |
|---|---|
| Organization Name | Hi Tech Prosthetics Inc |
| Location | 39 Ave Severiano Cuevas, Carr 107, Aguadilla, Puerto Rico 00603 |
| Type | Supplier |
| Phone | (787) 891-4805 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
A new study of liver patients by the University of Southampton shows that a Minimum Unit Price (MUP) policy for alcohol is exquisitely targeted towards the heaviest drinkers with cirrhosis.
Phillip Schnarrs, assistant professor in the UTSA Department of Kinesiology, Health and Nutrition, along with his collaborators, Amy Stone, associate professor of sociology and anthropology at Trinity University, and Robert Salcido from Pride Center San Antonio and Equality Texas, have been awarded a fellowship to study resilience in the LGBTQ+ populations in San Antonio and South Texas.
Eisai Inc., the U.S. pharmaceutical operation of Tokyo-based Eisai Co., Ltd., announced today that it has entered into an agreement with Arena Pharmaceuticals GmbH, a wholly owned subsidiary of Arena Pharmaceuticals, Inc., for exclusive U.S. rights to commercialize lorcaserin, a drug candidate for potential use in the treatment of obesity, including weight loss, for patients who are obese (Body Mass Index or BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related co-morbid condition.
The regulatory protein c-MYC plays an important role in promoting the development of many types of tumors. c-MYC is a transcription factor that controls the activity of large numbers of genes involved in cell division, and its overexpression leads to excessive cell proliferation.
A new study published in Chemrxiv in April 2020 describes the identification of 64 compounds that could potentially be inhibitors of replication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is causing the current COVID-19 disease pandemic. The research was carried out using a pharmacophore model of an essential viral enzyme, mining data from the Food and Drug Administration (FDA) database of conformations of approved drugs.
› Verified 5 days ago
News Archive
A new study of liver patients by the University of Southampton shows that a Minimum Unit Price (MUP) policy for alcohol is exquisitely targeted towards the heaviest drinkers with cirrhosis.
Phillip Schnarrs, assistant professor in the UTSA Department of Kinesiology, Health and Nutrition, along with his collaborators, Amy Stone, associate professor of sociology and anthropology at Trinity University, and Robert Salcido from Pride Center San Antonio and Equality Texas, have been awarded a fellowship to study resilience in the LGBTQ+ populations in San Antonio and South Texas.
Eisai Inc., the U.S. pharmaceutical operation of Tokyo-based Eisai Co., Ltd., announced today that it has entered into an agreement with Arena Pharmaceuticals GmbH, a wholly owned subsidiary of Arena Pharmaceuticals, Inc., for exclusive U.S. rights to commercialize lorcaserin, a drug candidate for potential use in the treatment of obesity, including weight loss, for patients who are obese (Body Mass Index or BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related co-morbid condition.
The regulatory protein c-MYC plays an important role in promoting the development of many types of tumors. c-MYC is a transcription factor that controls the activity of large numbers of genes involved in cell division, and its overexpression leads to excessive cell proliferation.
A new study published in Chemrxiv in April 2020 describes the identification of 64 compounds that could potentially be inhibitors of replication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is causing the current COVID-19 disease pandemic. The research was carried out using a pharmacophore model of an essential viral enzyme, mining data from the Food and Drug Administration (FDA) database of conformations of approved drugs.
› Verified 5 days ago
Diabetic Solutions Type: Medicare Supplier Location: Buen Samaritano Medical Professional Plaza, Aguadilla, Puerto Rico 00603 Phone: (787) 884-3382 | |
Walgreens #177 Type: Durable Medical Equipment & Medical Supplies Supplier Location: Carr #2 Km 129.7, Aguadilla, Puerto Rico 00605 Phone: (787) 882-8044 | |
Walgreens #15543 Type: Durable Medical Equipment & Medical Supplies Supplier Location: Carr .2 Int. 107, Km.125.5, Aguadilla, Puerto Rico 00603 Phone: (787) 819-3930 | |
Hitech Prosthetic, Inc. Type: Medicare Supplier Location: 39 Ave Severiano Cuevas, Aguadilla, Puerto Rico 00603 Phone: (787) 891-4805 |